PhysQuiz on ASCO GU: Renal Carcinoma
Are you caught up on breaking trial results released at ASCO GU? Test your knowledge on our Renal...
Read More
CID1591
New Data Stand Out for Health-Related Quality of Life in mRCC
Although the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated improved progression-free survival (PFS) and overall survival...
Read MoreMET Kinase Inhibitors Vs Sunitinib For pRCC
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...
Read MoreFollow-Up on Phase III JAVELIN Renal Trial: A+Ax vs S
Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101 In the phase III JAVELIN Renal 101...
Read MoreOutcomes Of First-Line Immuno-Oncology Combo in mRCC
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...
Read MoreTivozanib In Patients With aRCC
TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. The TIVO-3 study enrolled subjects with mRCC who failed two or three prior systemic regimens, one of...
Read MoreGenitourinary Cancers Symposium: New therapy prolongs survival for patients with urothelial carcinoma
Enfortumab vedotin (EV) will likely become the new standard of care for treating patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC). A recent phase 3 trial showed that treatment with...
Read MoreCabozantinib plus nivolumab provides better QoL than sunitinib
Although the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated superiority in progression-free survival (PFS) and overall...
Read MoreCLEAR Trial: Promising New Combination to Treat RCC
In the phase 3 multicenter, open-label, randomized CLEAR trial, lenvatinib in combination with pembrolizumab or everolimus demonstrated significant benefits over sunitinib in patients with advanced renal cell carcinoma (RCC)....
Read MoreUpdate on KEYNOTE-426: Combo Offers Durable Survival Benefit in Patients with Advanced Disease
Pembrolizumab plus axitinib is superior to sunitinib for the treatment of patients with treatment-naïve, advanced renal cell carcinoma (RCC), according to the most recent exploratory analysis of data from the KEYNOTE-426 study....
Read More
ASCO GU 2021: Axitinib offers hope for improving renal cell cancer surgical outcomes
Tyrosine kinase inhibitor axitinib elicited a 31% response rate in a phase 2 clinical trial that...
Read More
ASCO GU 2021: Better allocation of research dollars needed
Of nearly 80,000,000 USD in funding for bladder cancer research between 2017 and 2019,...
Read More
ASCO GU 2021: Superior clinical outcomes and quality of life with nivolumab plus cabozantinib in renal cell cancer
In CheckMate 9ER, patients with renal cell cancer (RCC) treated with nivolumab plus cabozantinib...
Read More
ASCO GU 2021: Enfortumab vedotin as treatment option for bladder cancer
Interim data from a clinical trial investigating the efficacy of enfortumab vedotin (EV) on...
Read More
ASCO GU 2021: New standard of care recommended for upper tract urothelial cancer
The Institute of Cancer Research in the UK found that the implementation of gemcitabine-platinum...
Read MoreResults from Phase 3 CLEAR Study for Advanced RRC
In patients with advanced RCC, second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone. LEN + PEMBRO, also showed preliminary efficacious evidence in a phase 1/2 RCC study. Here, we...
Read MoreData on Cabozantinib Activity in Brain Metastases in RCC
Results from a retrospective analysis evaluating (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC) will be presented as part of the Poster Session: Renal Cell Cancer at the 2021 American...
Read MorePhysQuiz Answers! ASCO GU: Renal Cell Carcinoma
1) Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC: a) pembrolizumab or...
Read More